1. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib—an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–28.
2. European Medicines Agency (EMA). Summary of Product Characteristics. XELJANZ 5 mg and 10 mg film-coated tablets.https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf. Accessed 2 Mar 2020.
3. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.
4. European Medicines Agency (EMA). Summary of Product Characteristics. Olumiant 2 mg and 4 mg film-coated tablets. https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf. Accessed 28 Jan 2020.
5. United States Food and Drug Administration (FDA). Highlights of prescribing information: OLUMIANT (baricitinib) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf. Accessed 2 Mar 2020.